[go: up one dir, main page]

WO2008019183A2 - Production de biopolymères et de protéines au moyen de systèmes de sécrétion de type iii de bactéries à gram négatif - Google Patents

Production de biopolymères et de protéines au moyen de systèmes de sécrétion de type iii de bactéries à gram négatif Download PDF

Info

Publication number
WO2008019183A2
WO2008019183A2 PCT/US2007/069300 US2007069300W WO2008019183A2 WO 2008019183 A2 WO2008019183 A2 WO 2008019183A2 US 2007069300 W US2007069300 W US 2007069300W WO 2008019183 A2 WO2008019183 A2 WO 2008019183A2
Authority
WO
WIPO (PCT)
Prior art keywords
protein
expression
bacterium
secretion
promoter
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/069300
Other languages
English (en)
Other versions
WO2008019183A3 (fr
Inventor
Christopher Ashby Voigt
Daniel Matthew Widmaier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California Berkeley
University of California San Diego UCSD
Original Assignee
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California Berkeley, University of California San Diego UCSD filed Critical University of California Berkeley
Publication of WO2008019183A2 publication Critical patent/WO2008019183A2/fr
Anticipated expiration legal-status Critical
Publication of WO2008019183A3 publication Critical patent/WO2008019183A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
    • C07K14/43586—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from silkworms

Definitions

  • Proteins have a variety of biological, therapeutic, commerical and industrial uses. Many potential high-value proteins are difficult to harvest from their natural source and their production in microorganisms has proven difficult due to cloning, expression, and toxicity issues.
  • natural biopolymers have evolved remarkable structural properties that are ideal materials for fabrics, plastics, glues and gums, and medical devices.
  • the family of spider silks include threads that are stronger than steel while maintaining flexibility and elastic properties.
  • Human-derived biopolymers, such as elastin are non- antigenic materials that can be used in medical devices. Many potential high-value biopolymers are particularly difficult to harvest from their natural source and their production in microorganisms has proven difficult due to cloning, expression, and toxicity issues.
  • Silks are protein-based biopolymer threads secreted by insects. They have evolved a remarkably wide range of desirable material properties. For example, the dragline threads that form the structural core of webs are stronger that Kevlar with ten times the elasticity. Changes in the amino acid sequence vary the flexibility, elasticity, strength, and stickiness of the threads. [0006] Many natural silks have materials, industrial, and medical applications. However, with few exceptions, it is impossible to farm and extract the source of the material. Spiders produce very small quantities of silk and they cannot be raised in high densities due to their territorial behavior. Thus, there has been much effort to use recombinant DNA to produce these materials in high yield.
  • Gram negative bacteria use type III secretion (TTSS) to translocate proteins from the cytoplasm, through both membranes, to the extracellular environment (Galan and Collmer, 1999).
  • a TTSS forms the core of several complex molecular machines, including the flagellum for swimming and molecular syringes that deliver effector proteins into plant and animal cells to promote pathogenesis and symbiosis (Huek, 1998; Chilcott and Hughes, 2000; Dale et al., 2002). While these systems are evolutionarily related, there are significant differences between their regulation, genomic organization, and supermolecular structure (Figure 3) (Aldridge and Hughes, 2002).
  • Gram negative bacteria use type III secretion to translocate proteins from the cytoplasm, through both membranes, to the extracellular environment (Galan and Collmer, 1999).
  • Salmonella is a well-equipped intracellular pathogen that contains two type III secretion systems and effector proteins that are injected into the host cell to facilitate invasion, disrupt the host cytoskeleton, direct organelle trafficking, alter host gene expression, and regulate apoptosis (Galan and Zhou, 2000; Haraga et al., 2003; Shotland et al., 2003; Hernandez et al., 2004). These systems are encoded in two regions of genome, referred to as pathogeneity islands. Salmonella Pathogeneity Island 1 (SPI-I) is required for bacteria to invade epithelial cells (Lee and Falkow, 1992). SPI-2 is expressed in the intracellular environment of macrophages (Cirillo et al., 1998).
  • the genes are synthesized by first making a codon optimized oligonucelotide of the repeat unit, which is then ligated to form a gene of a defined length.
  • First, the materials properties of natural silks rely on the non-repetitive portions of the sequence, especially variability in the glycine- rich elastic regions (van Beek et al., 2002). The non-repetitive are also important for nucleating the self-assembly of the fiber and maintaining solubility (Bini et al., 2004; Huemmerich et al., 2004a).
  • the artificial genes still suffer from recombination events due to DNA repetitiveness (Fahnestock et al., 1997a).
  • Silks based on artificial consensus repeat units often express well in yeast and bacteria.
  • artificial biopolymers based on the Nephila clavipes dragline sequence have been expressed at rates of 100 mg/L/day (Fahnestock et al., 1997a).
  • U.S. Patent Application Publication No. 20060068469 discloses the use of bacterial systems having a Type III secretion system to deliver proteins or polynucleotides to cells and animals. However, these systems rely upon the ability of the bacterium to enter a target cell or of the bacterium to lyse in the presence of a target cell.
  • this invention overcomes these difficulties by providing methods of making proteins by re-engineering gram negative bacteria having a Type III secretion system.
  • the invention provides an expression system based upon the Type III secretion system (TTSS) of gram negative bacteria.
  • the expression system comprises genetic control elements which link the expression of a heterologous gene to the completion of a functional TTSS in a gram negative bacteria.
  • the expression system can utilize a natural genetic circuit or recombinant/hybrid genetic circuit to link the heterologous gene expression to the completion of a functional TTSS. In some embodiments, these genetic circuits can serve to control when the TTSS is expressed as well as the order and magnitude of the expression of one or more heterologous genes.
  • the heterologous gene encodes a fusion protein comprising an N-terminal polypeptide tag and a protein of interest.
  • the protein of interest is not naturally occurring in bacteria.
  • the polypeptide tag serves as N-terminal secretion signal routing the peptide to the TTSS and can have the amino acid sequence of a native secretion signal tag or domain.
  • a tag is fused or attached to the protein of interest by an amino acid sequence which is subject to cleavage by a protease to be subsequently contacted with the fusion protein once it is secreted into the medium.
  • the chaperone utilized by the TTSS is co-expressed with the tagged heterologous protein.
  • the chaperone utilized by the TTSS is co-expressed with the tagged heterologous protein under the control of a sicA promoter.
  • the invention provides a gram negative bacterium expressing a heterologous protein which is capable of being secreted into a growth medium via the TTSS.
  • the bacterium has an expression system comprising genetic control elements which link the expression of a heterologous gene to the completion of a functional TTSS in a gram negative bacteria.
  • the bacterium is Salmonella, E. CoIi, Yersinia, Shigella, and Bordetella.
  • the bacterium is Salmonella typhimurium, and in still further embodiments, Salmonella typhimurium 1344.
  • the bacterium may be engineered to also express a heterologous protease which may, additionally, be engineered for secretion via the TTSS as a fusion protein.
  • the bacterium may be modified so as to have a reduced or no ability to express an effector protein secreted by the secretion system. For example, multiple genes encoding effector proteins involved in virulence may be deleted or silenced.
  • the bacteria may have been modified to eliminate the dependence of TTSS secretion on the presence of a host cell.
  • the contact dependence genes of the bacteria can for instance be knocked out or modified to remove the contact dependence (requirement for a host cell) to increase secretion into the media.
  • the bacterium is incapable of infecting natural host cells.
  • the bacteria is in a growth medium free of mammalian cells.
  • the medium is free of cells which can be entered by the bacterium.
  • the medium comprises cells which consist of, or consist essentially of, the gram negative bacterium.
  • the heterologous protein comprises an N-terminal polypeptide tag and a protein of interest.
  • the polypeptide tag serves as N-terminal secretion signal routing the peptide to the TTSS and can have the amino acid sequence of the native secretion signal tag.
  • the tag is fused or attached to the protein of interest by an amino acid sequence which is subject to cleavage by a protease to be subsequently contacted with the fusion protein once it is secreted into the medium.
  • the invention provides a method of making a protein of interest or a fusion protein comprising the protein of interest, by expressing the protein in a gram negative bacterium having a type III secretion system and an expression system as described herein.
  • the protein is heterologous to the bacterium and is expressed as a fusion protein comprising the protein of interest and an N-terminal polypeptide sequence or tag that directs the fusion protein to the TTSS which secretes the fusion protein into the medium of the bacterium.
  • the fusion protein preferably comprises an amino acid sequence linking the tag and protein in which the amino acid sequence is subject to hydrolysis by a predetermined protease to be contacted with the fusion protein.
  • the secreted fusion protein may be isolated from the medium prior to contacting the secreted protein with the protease.
  • the secreted protein may be contacted with the protease in the medium.
  • the protein of interest may be isolated after it is released by contacting with the protease.
  • the protein of interest is obtained in a form which is 90%, 95%, 99%, or 99.9% free by weight percent of other proteins.
  • the protein is a therapeutic protein, enzyme, growth factor, hormone, cytokine, an antibody, or a fibroin.
  • the protein of interest is human or mammalian.
  • the protein is secreted into the media and, hence, is much less likely to form "inclusion bodies.” Inclusion bodies form in cells when protein accumulates in large quantities (like bubbles). This is toxic and it is difficult to extract the protein afterward because the inclusion bodies will not dissolve.
  • the protein is not a protein which specifically binds a polynucleotide.
  • the invention provides methods of making pharmaceutical compositions comprising a therapeutic protein or a therapeutic fusion protein made by use of the above described methods, bacterium, or expression systems.
  • the proteins may be formulated for any suitable method of administration according to the target site for the administration and effect sought.
  • the therapeutic protein comprises or is a human or mammalian protein.
  • the invention provides polynucleotides encoding a fusion protein which comprises a protein of interest heterologous to gram negative bacterium and a tag sequence of gram negative bacterium.
  • the bacterium in some embodiments is Salmonella, E. CoIi, Yersinia, Shigella, and Bordetella. In some further embodiments, the bacterium is Salmonella typhimurium, and in still further embodiments, Salmonella typhimu ⁇ um 1344.
  • the protein of interest is a fibroin protein or a therapeutic protein. In some embodiments, the protein of interest is a therapeutic protein, enzyme, growth factor, hormone, cytokine, or an antibody.
  • the protein of interest is human or mammalian.
  • the tag and the protein of interest are joined by an linker sequence amino acid sequence which is optionally has a sequence subject to cleavage by a predetermined protease to be contacted in vitro.
  • the polynucleotides are used in the above described expression systems, bacterium, and methods of making proteins or pharmaceutical compositions.
  • the invention provides a vector or expression cassette comprising the above-described polynucleotides.
  • the vector is capable of or suitable for transfecting or transducing a bacterium.
  • the bacterium is Salmonella, E. CoIi, Yersinia, Shigella, Salmonella, and Bordetella.
  • the bacterium is Salmonella typhimuriiim, and in still further embodiments, Salmonella typhimurium 1344.
  • the polynucleotide is operably linked to a gene regulatory element that coordinates the expression of the protein of interest encoded by the polynucleotide with a functioning Type III secretion system.
  • the invention provides a kit comprising a gram negative bacterium having no or reduced expression of an effector secreted by a Type III secretory system of the bacterium and a vector comprising a gene regulatory element, wherein the element is capable of coordinating the expression of a polynucleotide operably linked to the element with a functional TTSS system.
  • the bacterium is Salmonella, Salmonella typhimurium, or Salmonella typhimurium 1344.
  • the kit comprises a first container holding a Salmonella bacterium having no or reduced expression of an effector secreted by a Type III secretory system, and a second container holding a polynucleotide encoding a sicA promoter.
  • the chaperone for the tagged heterologous protein is co-expressed with the tagged heterologous protein.
  • the chaperone utilized by the TTSS is co-expressed with the tagged heterologous protein under the control of a sicA promoter.
  • Figure 1 Amino acid sequence of some exemplary human polymers.
  • Figure 2 Amino acid sequence of some exemplary TTSS secretion signals.
  • FIG. 1 Regulatory Control of SPI-I . Regulatory interactions are colored by the order that they are activated in inducing conditions (top). A circuit diagram for this network is shown (bottom).
  • FIG. 4 A genetic circuit links effector expression to the completion of the TTSS.
  • the effectors SipB and SipA (dark circle) bind to the chaperone SicA.
  • the chaperone is free to bind to the transcription factor InvF. This activates the transcription factor, which upregulates effectors from the internal sicA promoter,
  • the SicP chaperone directs the SptP effector for secretion.
  • FIG. 6 When the input signal is removed via dilution, the sicA promoter demonstrates hysteresis.
  • A Flow cytometry data for the hilC and sicA promoters are shown (from top to bottom: 40, 205, 280, 380 minutes). The hilC and hilD promoters do not show hysteretic effects (B), but sicA does (C).
  • FIG. 7 SPI-I promoters exhibit both graded and all-or-none induction dynamics.
  • the induction of SPI-I promoters of the initial activator HilC (left), the prg operon encoding the TTSS inner membrane ring (center), and the sicA promoter controlling the expression of effectors (right) is shown as a function of OD. From top to bottom, the OD600 is 0.4, 0.6, and 1.8.
  • FIG. 8 An expression time course is shown for the wild-type (SLl 344) and AinvE Salmonella strains. Each lane is secreted protein, obtained by precipitating the supernatant. The AinvE strain secretes significantly more protein and significant expression and secretion is observed after eight hours.
  • the positive control is a standard FLAG-tagged protein at a concentration corresponding to 3 mg/L.
  • FIG. 9 Secretion of Spider Silk.
  • a Western blot is shown of the ADF-3 monomer fused to a FLAG tag. Protein was recovered using a secretion assay as described previously (Lee and Galan, 2004).
  • Figure 10 Amino acid sequence of FLAG tag.
  • FIG. 11 The Salmonella type III secretion system is harnessed to export spider silk proteins.
  • a synthetic control system (right) is constructed on a plasmid, and receives information from the natural regulatory network controlling TTSS self-assembly and function (left).
  • TTSS self-assembly is initiated by three transcription factors (HilC/D/A), which integrate environmental information. In turn, they initiate a transcriptional cascade that regulates the timing of the transcription of multiple operons.
  • An operon containing the chaperones and effectors (SicA) is controlled by a genetic circuit that becomes active once the TTSS is constructed and functional.
  • This genetic circuit is used to drive the expression of a chaperone (SicP) and silk protein fused to an N-terminal secretion signal (SptP), all of which are encoded on the pCASP plasmid. After secretion, the signal sequence (SptP) is removed by the TEV protease.
  • SerP chaperone
  • SptP N-terminal secretion signal
  • FIG. 12 The type III secretion system is assembled by an ordered transcriptional cascade with a genetic circuit linking the upregulation of secreted effectors to the completion of functional secretion needles, (a) The temporal ordering of the SPI-I promoters is shown using gfp fusion reporters and flow cytometry. First, the transcriptional regulators hilD ( ⁇ ) and MIC (x) accumulate. These regulators turn on the prgH promoter (o), which controls structural genes in the needle complex. Once the TTSS is functional, the effectors are strongly upregulated from the sicA promoter (+).
  • the type III secretion system can export heterologous proteins.
  • the human DH domain is used to determine secretion efficiency and longevity, (a) The DH domain is secreted when fused to the N-terminal SptP secretion signal and the SicP chaperone is co-transcribed (+SicP DH SLl 344). There is no change in secretion when the flagella master transcriptional regulators are knocked out, demonstrating that secretion is flagella independent (DH ⁇ FlhCD). The quantity of protein secreted is dramatically reduced when the SicP chaperone is not co-transcribed (wt SicP).
  • DH band is confirmed by immunoprecipitation of the protein from supernatant (DH Purified), the second band of higher molecular weight is the heavy chain of the FLAG antibody.
  • DH Purified the second band of higher molecular weight is the heavy chain of the FLAG antibody.
  • a western blot showing the periplasmic protein MaIE is detectable in the lysate but not in either the wild-type or DH supernatants. This indicates that lysis is not significantly contributing to the proteins isolated from the secretion assay.
  • FIG 14. The expression and secretion of four Araneus diadematus spider silk monomers is shown. Each silk gene was optimized to eliminate repetitive DNA and rare codons.
  • the sequence entropy (Methods) was calculated as a measure of diversity for an alignment of the repeat units. The optimized genes (black bars) have more sequence diversity than the wild-type genes (clear bars),
  • the change in codon usage is shown. The E. coli codon abundances were obtained from the KEGG database and averaged over the entire gene, (c) Very rare codons (defined as abundances ⁇ 0.13) were entirely eliminated from the sequences,
  • a secretion assay is shown for the optimized ADF-I, 2, 3, and 4 genes (Lanes 2-5).
  • TEV protease cleaves the SptP secretion tag from silk proteins.
  • ADF-2 prior to digestion is reduced in size by 19kD when the SptP secretion tag is removed by TEV protease.
  • Figure 15 The expression plasmid for heterologous secretion (pCASP).
  • FIG. 17 Comparison of secretion tags.
  • Each lane shows a secretion assay for different SPI-I tags fused to the DH protein. In each case (except InvJ), the corresponding chaperone was co-expressed from the sicA promoter. The SptP tag yielded the highest secretion yield.
  • FIG. 18 The utility of the sicA promoter is shown, (left) An assay is performed to quantify the formation of inclusion bodies in the cell. When the silk genes are expressed from an IPTG-inducible promoter (PTRC), the ADF-3 and ADF-4 monomers form tight inclusion bodies. The expression from the sicA promoter produces less protein in the form of inclusion bodies, (right) The silk proteins can also be toxic when expressed and not secreted.
  • PTRC IPTG-inducible promoter
  • the expression from the sicA promoter produces less protein in the form of inclusion bodies, (right)
  • the silk proteins can also be toxic when expressed and not secreted.
  • the invention relates to the use and modification of TTSS secretion system in gran negative bacteria to manufacture proteins.
  • the invention provides a method of making a protein of interest by expressing the protein in a gram negative bacterium having a type III secretion system wherein the protein is heterologous to the bacterium and the protein is fused to a polypeptide or tag that directs the protein to the secretion system so that the protein is secreted via the secretion system into the medium of the bacterium.
  • the bacterium is Salmonella, E. CoIi, Yersinia, Shigella, Chlamydia, or Bordetella. More preferably, the bacterium is Salmonella typhimu ⁇ um, and still more preferably, the bacterium is Salmonella typhimurium 1344.
  • the bacterium has a reduced ability to express a native effector protein secreted by the secretion system. For instance, multiple genes encoding effector proteins involved in virulence have been deleted or silenced.
  • the Type III secretion system is an SPI-I secretion system.
  • the bacterial strain used had contact dependence genes which have been knocked out to remove the contact dependence (requirement for a host cell) to increase secretion from the resulting strain into the media.
  • the heterologous protein or protein of interest can be a therapeutic protein, including human proteins.
  • the heterologous protein or protein of interest is isolated from the medium and formulated with a pharmaceutically acceptable carrier.
  • the heterologous protein is a spider silk protein, an ADF protein, a silk worm silk protein, or elastin.
  • a tag is coupled to the protein by a sequence of amino acids which is cleavable by an enzyme and the secreted protein is contacted with the enzyme and cleaved by the enzyme.
  • the enzyme is TEV protease and the sequence comprises the TEV recognition sequence.
  • the bacterium can be preferably modified to limit or eliminate their pathogenicity.
  • the protein of interest is encoded by a gene wherein the DNA was structurally stabilized and optimized for expression in bacteria through codon optimization, mRNA minimization, and reduction of recombination frequency.
  • the heterologous protein is expressed by a gene on a plasmid.
  • the expression of the protein is controlled by a genetic circuit that links the activation of expression to the completion of the TTSS structure.
  • the expression of the heterlogous protein can be operably linked or under the control of the sicA promoter in Salmonella.
  • the expression of the protein is controlled by a SPI-I promoter (e.g., hilC, hilD, hilA, invF, sopE, and prgH).
  • the bacterium is Salmonella and the tag is a tag of a Salmonella effector and the tag is an SptP effector tag (e.g., a tag comprising the sequence of SEQ ID No:l or SEQ ID No:2.
  • microbial or Salmonella codons can be substituted for insect codons in the gene expressing the protein.
  • the repeat regions and mRNA structures are reduced by making use of the codon degeneracies.
  • the heterologous protein or protein of interest is a protein that can modify a chemical/biopolymer/substrate that cannot pass through the cellular membrane of the bacterium.
  • the expression of the heterologous protein e.g., cellulase
  • a stationary phase promoter e.g., spvA, spvR, and ssaG.
  • the tag is the tag of the SopE, InvJ, or Sip A effectors.
  • the SPI-2 and flagella can be knocked out or inactive.
  • one or more extracellular or intracellular proteases of the bacterium are knocked out or inactive.
  • the expression of the protein of interest is under the control of a constitutive promoer or an inducible promoter (e.g., lac, tet, PBAD, etc.) as known to one of ordinary skill in the art.
  • a constitutive promoer or an inducible promoter e.g., lac, tet, PBAD, etc.
  • hybrid promoters that are IPTG inducible can be used to control the expression.
  • lac operator sites can be located on either end of the promoter (e.g, sicA, spvA, or ssaG).
  • a sicA promoter drives the expression of T7 polymerase whch then very strongly upregulates a T7 promoter.
  • the expression system comprises one or more genetic control element(s) which link the expression of a heterologous gene to the completion of a functional TTSS in a gram negative bacteria.
  • the invention also provides fusion proteins of a protein of interest and a polypeptide tag in which the protein is heterologous to wild-type Salmonella, and the tag directs a protein to a Salmonella Type III secretion system.
  • the protein comprises a spider silk protein; a silk worm silk protein; elastin; a fibroin; or a protein-based biopolymer; a blood or plasma protein; a mammalian peptide hormone, growth factor, cytokine, antibody, enzyme, or receptor.
  • the tag is linked to a protein of interest via a amino acid sequence subject to hydrolysis by a predetermined protease which is specific to the amino acid sequence insofar as it does not internally cleave the protein of interest.
  • the protein further comprises a polypeptide tag or label used in the detection or purification of the protein.
  • the contact dependence genes are knocked out to remove the contact dependence (requirement for a host cell) for increased secretion into the media. Accordingly, in some embodiments of any of the above, the bacterium is modified so as to not be able to enter a host cell. In some embodiments, the bacterium is modified so as to not lyse upon contact with a host cell. In other embodiments, the contact dependence genes are knocked out to remove the contact dependence
  • the bacterium has a reduced ability to express an effector protein (e.g., wild type effector proteins, pathogenic effector proteins) secreted by the secretion system.
  • an effector protein e.g., wild type effector proteins, pathogenic effector proteins
  • multiple genes encoding effector proteins involved in virulence can be deleted or silenced.
  • the Type III secretion system is an SPI-I secretion system.
  • the bacterium is modified so as not to bind a host cell or interact with a host cell it normally infects.
  • the tag is coupled to the protein by a sequence of amino acids which is cleavable by an enzyme and the secreted protein is contacted with the enzyme and cleaved by the enzyme.
  • the protease can be TEV protease and the sequence is the TEV recognition sequence.
  • the consensus TEV recognition sequence is Glu-X-X-Tyr-X-Gln/Ser. Cleavage occurs between the conserved GIn and Ser residues.
  • X can be various amino acyl residues but note that not all residues are tolerated, (see, Dougherty et al. 1989. Virology 171 :356-364).
  • the polynucleotide or gene encoding the protein of interest can be structurally stabilized and optimized for expression in bacteria through codon optimization, mRNA minimization, and reduction of recombination frequency.
  • the repeat regions and mRNA structures of fibroins can be reduced by making use of the codon degeneracies.
  • the heterologous protein or protein of interest can be expressed by a gene on a plasmid in the bacterium. Additionally, in such embodiments, the expression of the protein is preferably controlled by a genetic circuit that links the activation of expression to the completion of the TTSS structure. Accordingly, in some embodiments of the invention in any aspect, the heterologous protein is expressed under the control of the sicA promoter or a SPI-I promoter. Suitable promoters include, but are not limited to, hilC, hilD, hilA, invF, sopE, and prgH. In still other embodiments, the expression of the protein is controlled by a stationary phase promoter. Suitable stationary phase promoters are also contemplated in some embodiments, These promoters include, but are not limited to, spvA, spvR, and ssaG.
  • the expression of the protein is under the control of a hybrid promoter system that is IPTG inducible.
  • promoters e.g., sicA, spvA, ssaG
  • lac operator sites i.e., at either end of a promoter.
  • the regulatory protein Lad binds to two sites and causes the promoter to loop, which shuts it off.
  • the promoter opens up and the promoters are active (only if the bacterium is in the correct growth/secretion state).
  • competing secretion systems are either knocked out, not activated, or not expressed. These knocked out systems include, but are not limited to, including SPI-2 and flagella.
  • extracellular and/or intracellular proteases are knocked out, not activated, or not expressed. Combinations of such knockouts (e.g., competing secretion systems, effector knockouts, and protease knockouts) provide a secretion/expression optimized strain of the bacterium (e.g., Salmonella, E. CoIi, Yersinia, Shigella, Chlamydia, and Bordetella).
  • control circuit serves to amplify the sicA promoter to increase expression/secretion.
  • sicA promoter drives the expression of T7 polymerase, which then very strongly upregulates a T7 promoter. This strategy allows greater expression, while still only turning on when the TTSS is complete and functional.
  • the heterologous protein is introduced on a plasmid in which expression is controlled by a genetic circuit that links the activation of expression to the completion of the TTSS structure. For instance, specifically, this can be done by putting the gene under the control of the sicA promoter. Via a chaperone feedback mechanism, this promoter is only turned on when the TTSS is built and is functional. This avoids the expression and accumulation of potentially toxic proteins before the secretion system is ready.
  • sicA to be a remarkably strong promoter; much stronger than many common inducible systems.
  • the SPI-I system is particularly advantageous over other secretion systems in Salmonella because its induction was easily controlled in culture. It can be induced uniformly through the cells in standard LB media. To avoid the expression of SPI-I, the bacteria can be grown in other standard medias, such as M9 minimal media and Rich Broth, where SPI-I is not induced. Accordingly, in some embodiments, the culture conditions used to culture the bacteria can be selected to avoid expression and bypass the load imposed by massive overexpression, until desired.
  • the SPI-I can also be induced artificially by using control elements which allow the HiIC and HiID transcriptional activators to be expressed under conditions wich otherwise would be non-inducing for SPI-I or in a media where the needle would not otherwise be naturally activated.
  • the bacterium is Salmonella and the tag is a tag of a Salmonella effector.
  • the tag is an SptP effector tag.
  • the tag comprises the sequence of SEQ ID No:l, SEQ ID No:2. or SEQ ID NO:3 or one substantially identical thereto. Suitable tags include those of the SopE, InvJ, or SipA effectors.
  • hilD is placed under inducible control.
  • the initiation of SPI-I is controlled by the HiID transcriptional activator.
  • This also is the primary activator of the prg operon, which controls the number of needles that are constructed (Kubori et al., 2000).
  • Secretion can be increased by overexpressing the HiID transcriptional activator from an inducible plasmid.
  • the expression of the protein is optimized by substituting Salmonella codons for insect codons in the gene expressing the protein.
  • a plurality of proteins of interest can be expressed in one bacterium using the above systems.
  • the proteins can be encoded on genes of the same polynucleotide, vector, or plasmid. They can be subject to the control of the same gene regulatory elements.
  • the proteins are capable of being spun together into a fiber.
  • they are silk or fibroin proteins are each from the same or different species.
  • bioreactor fermentations are adjusted to maintain SPI-I optimal conditions over a longer period of time.
  • tags are based upon the SptP secretion signal.
  • secretion signals corresponding or having the sequence of SipA, SopE, and InvJ are contemplated.
  • the invention also provides 1) polynucleotides encoding the above described protein(s) and/or expression control systems and 2) gram negative bacterium (e.g., Salmonella, E. CoIi, Yersinia, Shigella, Chlamydia, and Bordetella), transfected with the polynucleotides.
  • gram negative bacterium e.g., Salmonella, E. CoIi, Yersinia, Shigella, Chlamydia, and Bordetella
  • These bacterium can be modified to provide no or reduced expression of an effector secreted by the Type III secretory system used to secrete the protein in the bacterium.
  • the invention also provides vectors or expression cassettes comprising the above- described polynucleotides.
  • the vector or expression cassette has the polynucleotide operably linked to a gene regulatory element that coordinates the expression of the protein encoded by the polynucleotide with a functioning Type III secretion system (e.g., the Salmonella SPI-I TTSS).
  • the invention also provides kits.
  • the kit can comprise a Salmonella bacterium or other bacterium ⁇ Salmonella, E. CoIi, Yersinia, Shigella, Chlamydia, and Bordetella) having no or reduced expression of an effector secreted by a Type III secretory system and a vector or expression cassette comprising a gene regulatory element capable of coordinating the expression of a polynucleotide with the expression of a functioning Type III secretory system in the bacterium.
  • the bacterium are preferably modified to limit or eliminate their pathogenicity.
  • the invention provides a kit having a first container holding a Salmonella bacterium having no or reduced expression of an effector secreted by a Type III secretory system, and a second container holding a polynucleotide encoding a sicA promoter.
  • the bacterium is Salmonella, Salmonella typhimurium, or Salmonella typhimurium 1344.
  • the strain is Salmonella typhimurium 1344 which is not a lab strain.
  • the strain is a knocked out strain which knock-outs serve to increase secretion, expression, adnd/or eliminate virulence.
  • Salmonella typhimurium 1344 SP-I TTSS can be turned into a secretion-competent expression strain analogous to E. CoIi BL21.
  • the protein or fusion protein according to the invention is labeled.
  • the label can be used to detect or facilitate isolation of the compound as known to one of ordinary skill in the art.
  • the label is part of a fusion protein and encoded by the polynucleotide encoding the secretion amino acid tag and the protein of interest.
  • a "label” or a “detectable moiety” is a composition detectable by spectroscopic, photochemical, biochemical, immunochemical, chemical, or other physical means.
  • useful labels include 32P, fluorescent dyes, electron-dense reagents, enzymes (e.g., as commonly used in an ELISA), biotin, digoxigenin, or haptens and proteins which can be made detectable, e.g., by incorporating a radiolabel into the peptide or used to detect or be detected by antibodies specifically reactive with the peptide.
  • the label can be used to detect or facilitate isolation of the compound.
  • the label can be linked to the protein or fusion protein by an amino acid sequence which is subject to hydrolysis by a protease.
  • the amino acid sequence can be subject to hydrolysis by the same enzyme used to cleave the link between the secretion tag sequence and the protein of interest (e.g., the amino acid sequences to be cleaved can be the same or susceptible to hydrolysis by the same enzyme, optionally performed in the same step).
  • Regulatory genes are encoded in the Salmonella pathogeneity island that control the commitment to needle production and internally regulate the gene expression order.
  • the SPI-I regulatory network is centered around a four-tiered cascade ( Figure 3).
  • There is an initiation circuit (centered on HilC/D/A) that integrates many environmental signals and commits to needle formation (Lucas and Lee, 2000).
  • the cascade controls the order in which different operons are expressed. This order is required for the proper assembly of the needle (Sukhan et ah, 2001).
  • a TTSS genetic circuit links the completion of functional needles with the upregulation of effector expression (Figure 4) (Darwin and Miller, 2001).
  • the core of the circuit is formed by an interaction between a chaperone (SicA), effectors (SipB/C), and a transcription factor (InvF).
  • SerA chaperone
  • SipB/C effectors
  • InvF transcription factor
  • the chaperone is titrated out by an overabundance of effector.
  • the effector is released, which frees the chaperone to bind to the transcription factor. Only in this bound state can the transcription factor activate promoters to upregulate effector expression.
  • the Salmonella SPI-I TTSS forms a needle-like structure that projects from the cytoplasm, through the inner and outer membrane, and extends 50 nanometers from the cell surface. Under fully activating conditions, there are several hundred needles per cell. Effectors are directed to the needle structure by chaperones, which bind to an N-terminal secretion signal . Proteins are probably passed through the needle in a partially non-globular state (Stebbins and Galan, 2003).
  • the chaperones have the capability maintain the effectors in a semi-unfolded state and do not require nucleotide hydrolysis to function (Stebbins and Galan, 2001) and the needle pore is -30 angstroms wide, which is large enough to allow small folded proteins to pass. All of the necessary structural proteins, chaperones, and most of the effectors exist as a single contiguous island in the genome. Accordingly, in some further embodiments of any of the above aspects, the heterologous protein is a small folded protein.
  • the Salmonella pathogeneity island also contains genes that encode transcription factors that internally regulate the order and conditions in which different genes are expressed.
  • the SPI-I regulatory network is centered around a four-tiered cascade.
  • a genetic circuit links the completion of functional needles with the upregulation of effector expression in Salmonella.
  • this circuit as part of our expression system to ensure that the heterologous proteins are only expressed when the system is capable of secreting them out of the cell.
  • the core of the circuit is formed by an interaction between a chaperone (SicA), an effector (SipB/C), and a transcription factor (InvF).
  • SicA chaperone
  • SipB/C effector
  • InvF transcription factor
  • the major secretion systems used in the laboratory include the Sec system and the twin arginine translocation (TaT) system (Pohlschroder et al., 2005), both of which deliver protein to the periplasm rather than the extracellular environment.
  • the Sec system is well characterized and involves a short signal sequence that localizes pre- protein to the cytoplasmic membrane.
  • the Sec translocon hydrolyzes ATP and translocates the unfolded pre-protein into the periplasmic space.
  • the TaT system is used to translocate folded proteins across the bacterial membrane.
  • TaT secretes proteins into the periplasmic space rather than the extracellular environment.
  • the flagellar export system has been used to secreting heterologous proteins in quantities of 1-15 mg/L (Majander et al., 2005).
  • There are several problems with the flagellar system Only a small number of flagella are produced by each cell (even when over expressed, only 10s are present).
  • polypeptide polypeptide
  • peptide protein
  • protein protein
  • amino acid polymers in which one or more amino acid residue is an artificial chemical mimetic of a corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers and non- naturally occurring amino acid polymer.
  • Methods for obtaining (e.g., producing, isolating, purifying, synthesizing, and recombinantly manufacturing) polypeptides are well known to one of ordinary skill in the art.
  • amino acid refers to naturally occurring and synthetic amino acids, as well as amino acid analogs and amino acid mimetics that function in a manner similar to the naturally occurring amino acids.
  • Naturally occurring amino acids are those encoded by the genetic code, as well as those amino acids that are later modified, e.g., hydroxyproline, ⁇ - carboxyglutamate, and O-phosphoserine.
  • Amino acid analogs refers to compounds that have the same basic chemical structure as a naturally occurring amino acid, i.e., an ⁇ carbon that is bound to a hydrogen, a carboxyl group, an amino group, and an R group, e.g., homoserine, norleucine, methionine sulfoxide, methionine methyl sulfonium. Such analogs have modified R groups (e.g., norleucine) or modified peptide backbones, but retain the same basic chemical structure as a naturally occurring amino acid.
  • Amino acid mimetics refers to chemical compounds that have a structure that is different from the general chemical structure of an amino acid, but that functions in a manner similar to a naturally occurring amino acid.
  • Amino acids may be referred to herein by either their commonly known three letter symbols or by the one-letter symbols recommended by the IUPAC-IUB Biochemical Nomenclature Commission. Nucleotides, likewise, may be referred to by their commonly accepted single-letter codes.
  • conservatively modified variants of amino acid sequences
  • amino acid sequences one of skill will recognize that individual substitutions, deletions or additions to a nucleic acid, peptide, polypeptide, or protein sequence which alters, adds or deletes a single amino acid or a small percentage of amino acids in the encoded sequence is a "conservatively modified variant” where the alteration results in the substitution of an amino acid with a chemically similar amino acid.
  • Conservative substitution tables providing functionally similar amino acids are well known in the art.
  • Such conservatively modified variants are in addition to and do not exclude polymorphic variants, interspecies homologs, and alleles of the invention.
  • the following eight groups each contain amino acids that are conservative substitutions for one another: 1) Alanine (A), Glycine (G); 2) Aspartic acid (D), Glutamic acid (E); 3) Asparagine (N), Glutamine (Q); 4) Arginine (R), Lysine (K); 5) Isoleucine (I), Leucine (L), Methionine (M), Valine (V); 6) Phenylalanine (F), Tyrosine (Y), Tryptophan (W); 7) Serine (S), Threonine (T); and 8) Cysteine (C), Methionine (M) (see, e.g., Creighton, Proteins (1984)).
  • a "protein of interest” can be any protein, including but not limited to, protein drug, therapeutic protein, cytokine, enzyme, hormone, receptor, growth factor, fibroin with the proviso that the protein is heterologous to the wild-type of the bacterium used to express the protein or fusion protein thereof.
  • the protein of interest preferably can be a naturally occurring human, mammalian, or insect protein or one which is substantially identical thereto, or a conservatively modified variant thereof.
  • the protein can have the amino acid sequence of a naturally occurring human, mammalian or insect protein.
  • the protein can be elastin, a fibroin or protein-based biopolymers, including spider silks. It can be a silk fiber protein, including spider silk proteins and silk worm silk proteins.
  • the protein can be ADF- 3.
  • the silk proteins can be reengineered to increase their strength as known to one of ordinary skill in the art or to facilitate their expression in the bacterial system employed in their manufacture.
  • the protein e.g., cellulose
  • the protein may be one which modify a chemical/biopolymer/substrate (e.g., cellulose) that cannot pass through a cellular membrane.
  • the protein can be a protein component of blood or plasma.
  • the protein can be multi-component silk biopolymers (silk worm, other moths, spiders), abductin (a strong glue- like biopolymer from mollusks), elastin and other human extracellular matrix proteins, or sericins and gum proteins (from insects).
  • a protein can be ADF-I , ADF-2, ADF-3 or ADF-4.
  • ADF-3 for instance, is a dragline silk.
  • ADF-I and ADF-2 are flagelliform (the circles in a web) and ampullate (egg sack) silks.
  • ADF-4 is a dragline silk with different properties than ADF-3.
  • the protein is an artificial protein-based biopolymer based on consensus repeat amino acid sequences.
  • the protein is a biopolymer or fibroin that contains heterologous functional domains inserted into their sequence (e.g., enzymes or functional groups that promoter cell adhesion or other domain that is beneficial for a medical device).
  • the proteins of interest are capable of forming threads, fibers, films.
  • the proteins may be able to self-assemble or to be spun by machinery into the threads or fiber as is known to one of ordinary skill in the art.
  • Some suitable spider silks are described in Rising et al. Zoological Science, 22: 273-281 (2005).
  • Drag line silk proteins are also suitable. Once obtained, silk proteins and fibroins and the like can be mechanically spun from monomelic solutions as known to one of ordinary skill in the art.
  • the heterologous protein further is not a bacterial protein or is not an effector protein found in a wild-type bacteria.
  • the heterologous protein further is not a naturally occurring bacterial protein. In some embodiments, the heterologous protein further does not specifically bind nucleic acids. In some embodiments, the protein further is not an effector protein. In some embodiments in any aspect, the protein of interest can be at least 10, 20, 30, 40 or 50 amino acids long. For instance, the protein of interest can be from 10 to 50 amino acids long, 20 to 100 amino acids long, or 40 to 200 amino acids long, or 200 to 400 amino acids in length.
  • the "proteins of interest” can be obtained by hydrolysis of a fusion protein comprising the protein of interest by a protease specific for the amino acid sequence joining or linking the protein of interest to the tag sequence in the fusion protein.
  • the proteins may be further isolated and purified as known to one of ordinary skill in the art. If intended for pharmaceutical uses, the proteins may be formulated with a pharmaceutically acceptable carrier.
  • a protein of interest can be a protein which is identical or substantially identical to a naturally occurring protein.
  • a protein of interest may differ from a naturally occurring protein according one, two, three or more conservative amino acid substitutions.
  • Proteins of interest include therapeutic proteins.
  • Therapeutic proteins are polypeptides which are administered to treat a disease or disorder in a subject.
  • the subject can be a human, primate, mammal, or any animal.
  • the therapeutic proteins can be, for instance, an antibody (monoclonal or polyclonal, and/or humanized antibody), an enzyme, a hormone, a cytokine, a receptor, a ligand of a receptor, a clotting factor.
  • the therapeutic protein can be identical to or substantially identical to any mammalian or human enzyme, hormone, enzyme, cytokine, receptor, ligand for a receptor, or protein having a therapeutic use.
  • the protein of interest can be a protein that self-assembles into structure(s) with materials properties (fibers, threads, gums, films) important for industrial and medical applications.
  • the protein of interest is a natural fibroin, elastin, or other macrobiopolymer.
  • Fibroins represent a large family of natural polymers that self-assemble from monomelic protein subunits. Many insects, especially moths and spiders, build silk threads as part of their webs, cocoons, and egg sacks. Silk worm silk is used as a common material because of high production rates and ease of farming. However, other insects and spiders produce silks with varied and desirable properties, but do so in small amounts and many cannot be farmed.
  • Fibroins evolved a remarkably wide range of desirable material properties.
  • the dragline threads that form the structural core of webs are stronger that Kevlar with ten times the elasticity (Hinman et al, 2000).
  • Flagelliform silk can be stretched three times its length before breaking (Hayashi and Lewis, 2001).
  • Changes in the amino acid sequence vary the flexibility, elasticity, strength, and stickiness of the threads (Gosline et al., 1999; Gatsey et al., 2001).
  • Similar polymers are produced in higher animals, including humans, and are used to form the structural core of tissues and organs. The production of these proteins could be used as an non-antigenic material for medical devices.
  • Recombinant protein-based biomaterials can also be engineered to include functional domains that act as catalysts or guides for cell motility and tissue behavior (Maskarinec and Tirrell, 2005). Spider silk fibroins have also been shown to be useful in building artificial tissue (Tsubouchi et al., 2005; Dal Pra et al., 2005).
  • Spiders and insects have elaborate organelles that change the ambient conditions to spin the silk threads (Vollrath and Knight, 2001). Natural silks tend to be composed of two or more monomelic variants (Dicko et al., 2004). The insect can vary the physical properties of the thread by changing the spinning conditions and the relative composition of monomers. Purified monomers can self-assemble into threads when the pH of a solution is lowered (Huemmerich et al., 2004b). Long threads can be obtained using industrial polymer-spinning equipment). It has been shown that threads can be obtained from monomelic solutions of recombinant ADF-3 and ADF-4 (expressed in mammalian cells) that have similar properties of the natural silk (Lazarias et al., 2002).
  • the dragline thread of Araneus diadematus is primary comprised of two proteins: ADF-3 and ADF-4 (Huemmerich et al., 2004b). These biopolymers are made up of alternating alanine- and glycine- rich repeat sequences that give the thread its mechanical and elastic properties, respectively (Gosline et al., 1999). Dragline silk for the structural anchor of the web and has the strongest and physical properties, while maintaining elasticity (Gosline et al., 1999). In addition to the repetitive regions, there are non-repetitive domains at the N- and C- termini of the biopolymer.
  • Proteins have many medical and material uses, but they are too expensive to produce in bulk. This system is suitable for production of a variety of such biopolymers, including silkworm silk and human elastin. Elastin is a biopolymer that would be useful in making medical devices because it is extremely strong and not immunogenic. This method is also generally advantageous as in, for instance, the large scale production of heterologous protein.
  • proteins include, but are not limited to, proteins that have to be folded to be functional.
  • Nucleic acid or “polynucleotide” refers to deoxyribonucleotides or ribonucleotides and polymers thereof in either single- or double-stranded form.
  • the term encompasses nucleic acids containing known nucleotide analogs or modified backbone residues or linkages, which are synthetic, naturally occurring, and non-naturally occurring, which have similar binding properties as the reference nucleic acid, and which are metabolized in a manner similar to the reference nucleotides.
  • Examples of such analogs include, without limitation, phosphorothioates, phosphoramidates, methyl phosphonates, chiral-methyl phosphonates, 2-O-methyl ribonucleotides, peptide-nucleic acids (PNAs).
  • nucleic acid is used interchangeably with gene, cDNA, mRNA, oligonucleotide, and polynucleotide.
  • Polynucleotides may comprise a native sequence ⁇ i.e., an endogenous sequence that encodes an individual antigen or a portion thereof) of a protein of interest or may comprise a variant of such a sequence as set forth above. Polynucleotide variants may contain one or more substitutions, additions, deletions and/or insertions such that the biological activity of the encoded chimeric protein is not diminished, relative to a chimeric protein comprising native antigens.
  • Variants preferably exhibit at least about 70% identity, more preferably at least about 80% identity and most preferably at least about 90%, 95%, 96%, 97%, 98% or 99% identity to a polynucleotide sequence that encodes a native polypeptide or a portion thereof.
  • nucleic acid sequence also implicitly encompasses conservatively modified variants thereof (e.g., degenerate codon substitutions) and complementary sequences, as well as the sequence explicitly indicated.
  • degenerate codon substitutions may be achieved by generating sequences in which the third position of one or more selected (or all) codons is substituted with mixed-base and/or deoxyinosine residues (Batzer et al., Nucleic Acid Res. 19:5081 (1991); Ohtsuka et al., J. Biol. Chem. 260:2605-2608 (1985); Rossolini et al, MoI Cell. Probes 8:91-98 (1994)).
  • nucleic acid is used interchangeably with gene, cDNA, mRNA, oligonucleotide, and polynucleotide.
  • Methods of non-viral delivery of nucleic acids include lipofection, microinjection, biolistics, virosomes, liposomes, immunoliposomes, polycation or lipid:nucleic acid conjugates, naked DNA, artificial virions, and agent-enhanced uptake of DNA. Lipofection is described in, e.g., U.S. Patent No. 5,049,386, U.S. Patent No. 4,946,787; and U.S. Patent No.
  • An "expression cassette” refers to a polynucleotide molecule comprising expression control sequences operatively linked to coding sequence(s).
  • a "vector” is a replicon in which another polynucleotide segment is attached, so as to bring about the replication and/or expression of the attached segment.
  • Control sequence or "control element” refers to polynucleotide sequences which are necessary to effect the expression of coding sequences to which they are ligated. The nature of such control sequences differs depending upon the host organism; in prokaryotes, such control sequences generally include promoter, ribosomal binding site, and terminators; in eukaryotes, generally, such control sequences include promoters, terminators and, in some instances, enhancers.
  • control sequences is intended to include, at a minimum, all components whose presence is necessary for expression, and may also include additional components whose presence is advantageous, for example, leader sequences.
  • operably linked refers to a juxtaposition wherein the components so described are in a relationship permitting them to function in their intended manner.
  • a control sequence "operably linked" to a coding sequence is ligated in such a way that expression of the coding sequence is achieved under conditions compatible with the control sequences.
  • the TTSS genes are generally expressed over a remarkably wide range of growth phases (OD 6OO 0.1-2.2).
  • the natural SPI-I promoters can be combined with synthetic genetic circuits to create a regulatory 'assembly line,' where different genes are programmed to be expressed at different times. This approach is advantageous where biopolymer-modifying proteins are secreted at different stages of growth.
  • a protease can be secreted to automatically cleave the N-terminal secretion signal.
  • the TTSS system can be engineered to secrete a cellulase to convert cellulose, which does not cross the cell membrane, to glucose, which can be used for growth and as a metabolic precursor. This enables the conversion biomass into drugs, specialty chemicals, and energetic compounds.
  • Nucleic acid is "operably linked" when it is placed into a functional relationship with another nucleic acid sequence.
  • DNA for a presequence or secretory leader is operably linked to DNA for a polypeptide if it is expressed as a preprotein that participates in the secretion of the polypeptide;
  • a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence; or
  • a ribosome binding site is operably linked to a coding sequence if it is positioned so as to facilitate translation.
  • "operably linked” means that the DNA sequences being linked are near each other, and, in the case of a secretory leader, contiguous and in reading phase. However, enhancers do not have to be contiguous. Linking is accomplished by ligation at convenient restriction sites. If such sites do not exist, the synthetic oligonucleotide adaptors or linkers are used in accordance with conventional practice.
  • Each polynucleotide or gene can be codon optimized for expression in eubacteria and minimized for mRNA secondary structure.
  • the degeneracy of the codon code can be used to reduce the repetitiveness of the DNA to avoid homogenous recombination.
  • the performance of each gene can be tested for secretion in the expression system.
  • Constantly modified variants also applies to nucleic acid sequences. With respect to particular nucleic acid sequences, conservatively modified variants refers to those nucleic acids which encode identical or essentially identical amino acid sequences, or where the nucleic acid does not encode an amino acid sequence, to essentially identical sequences. Because of the degeneracy of the genetic code, a large number of functionally identical nucleic acids encode any given protein. For instance, the codons GCA, GCC, GCG and GCU all encode the amino acid alanine. Thus, at every position where an alanine is specified by a codon, the codon can be altered to any of the corresponding codons described without altering the encoded polypeptide.
  • nucleic acid variations are "silent variations," which are one species of conservatively modified variations. Every nucleic acid sequence herein which encodes a polypeptide also describes every possible silent variation of the nucleic acid.
  • each codon in a nucleic acid except AUG, which is ordinarily the only codon for methionine, and TGG, which is ordinarily the only codon for tryptophan
  • TGG which is ordinarily the only codon for tryptophan
  • nucleic acids or polypeptide sequences refer to two or more sequences or subsequences that are the same or have a specified percentage of amino acid residues or nucleotides that are the same (i.e., about 60% identity, preferably 65%, 70%,
  • the definition also includes sequences that have deletions and/or additions, as well as those that have substitutions.
  • the preferred algorithms can account for gaps and the like.
  • identity exists over a region that is at least about 25 amino acids or nucleotides in length, or more preferably over a region that is 50-100 amino acids or nucleotides in length.
  • sequence comparison typically one sequence acts as a reference sequence, to which test sequences are compared.
  • test and reference sequences are entered into a computer, subsequence coordinates are designated, if necessary, and sequence algorithm program parameters are designated.
  • sequence algorithm program parameters Preferably, default program parameters can be used, or alternative parameters can be designated.
  • sequence comparison algorithm then calculates the percent sequence identities for the test sequences relative to the reference sequence, based on the program parameters.
  • a “comparison window,” as used herein, includes reference to a segment of any one of the number of contiguous positions selected from the group consisting of from 20 to the full length of the reference sequence, usually about 25 to 100, or 50 to about 150, more usually about 100 to about 150 in which a sequence may be compared to a reference sequence of the same number of contiguous positions after the two sequences are optimally aligned.
  • Methods of alignment of sequences for comparison are well-known in the art. Optimal alignment of sequences for comparison can be conducted, e.g., by the local homology algorithm of Smith & Waterman, Adv. Appl. Math. 2:482 (1981), by the homology alignment algorithm of Needleman & Wunsch, J. MoI. Biol.
  • a prefei ⁇ ed example of algorithm that is suitable for determining percent sequence identity and sequence similarity are the BLAST and BLAST 2.0 algorithms, which are described in Altschul et al, Nuc. Acids Res. 25:3389-3402 (1977) and Altschul et al, J. MoI. Biol. 215:403-410 (1990), respectively.
  • BLAST and BLAST 2.0 are used, with the parameters described herein, to determine percent sequence identity for the nucleic acids and proteins of the invention.
  • Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information (http://www.ncbi.nlm.nih.gov/).
  • This algorithm involves first identifying high scoring sequence pairs (HSPs) by identifying short words of length W in the query sequence, which either match or satisfy some positive- valued threshold score T when aligned with a word of the same length in a database sequence.
  • T is referred to as the neighborhood word score threshold (Altschul et al, supra).
  • a scoring matrix is used to calculate the cumulative score. Extension of the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached.
  • the BLAST algorithm parameters W, T, and X determine the sensitivity "and speed of the alignment.
  • Naturally-occurring refers to the fact that the object can be found in nature.
  • a polypeptide or polynucleotide sequence that is present in an organism (including viruses) that can be isolated from a source in nature and which has not been intentionally modified by man in the laboratory is naturally-occurring.
  • stringent hybridization conditions refers to conditions under which a probe hybridizes to its target subsequence, typically in a complex mixture of nucleic acids, but to no other sequences. Stringent conditions are sequence-dependent and can be different in different circumstances. Longer sequences hybridize specifically at higher temperatures. An extensive guide to the hybridization of nucleic acids is found in Tijssen, Techniques in Biochemistry and Molecular Biology— Hybridization with Nucleic Probes, "Overview of principles of hybridization and the strategy of nucleic acid assays” (1993). Generally, stringent conditions are selected to be about 5-1O 0 C lower than the thermal melting point (T 1n ) for the specific sequence at a defined ionic strength pH.
  • the T m is the temperature (under defined ionic strength, pH, and nucleic concentration) at which 50% of the probes complementary to the target hybridize to the target sequence at equilibrium (as the target sequences are present in excess, at T m , 50% of the probes are occupied at equilibrium).
  • Stringent conditions may also be achieved with the addition of destabilizing agents such as formamide.
  • a positive signal is at least two times background, preferably 10 times background hybridization.
  • Exemplary stringent hybridization conditions can be as following: 50% formamide, 5x SSC, and 1% SDS, incubating at 42 0 C, or, 5x SSC, 1% SDS, incubating at 65 0 C, with wash in 0.2x SSC, and 0.1% SDS at 65 0 C.
  • nucleic acids that do not hybridize to each other under stringent conditions are still substantially identical if the polypeptides which they encode are substantially identical. This occurs, for example, when a copy of a nucleic acid is created using the maximum codon degeneracy permitted by the genetic code. In such cases, the nucleic acids typically hybridize under moderately stringent hybridization conditions.
  • Exemplary "moderately stringent hybridization conditions” include a hybridization in a buffer of 40% formamide, 1 M NaCl, 1% SDS at 37 0 C, and a wash in IX SSC at 45 0 C. A positive hybridization is at least twice background.
  • Those of ordinary skill will readily recognize that alternative hybridization and wash conditions can be utilized to provide conditions of similar stringency. Additional guidelines for determining hybridization parameters are provided in numerous reference, e.g., and Current Protocols in Molecular Biology, ed. Ausubel, et al, John Wiley & Sons.
  • a temperature of about 36°C is typical for low stringency amplification, although annealing temperatures may vary between about 32°C and 48°C depending on primer length.
  • a temperature of about 62°C is typical, although high stringency annealing temperatures can range from about 50 0 C to about 65°C, depending on the primer length and specificity.
  • Typical cycle conditions for both high and low stringency amplifications include a denaturation phase of 90 0 C - 95°C for 30 sec - 2 min., an annealing phase lasting 30 sec. - 2 min., and an extension phase of about 72°C for 1 - 2 min. Protocols and guidelines for low and high stringency amplification reactions are provided, e.g., in Innis et al. (1990) PCR Protocols, A Guide to Methods and Applications, Academic Press, Inc. N.Y.).
  • Knock-out cells and transgenic bacteria can be made by insertion of a marker gene or other heterologous gene into an endogenous gene site in the mouse genome via homologous recombination. Such mice can also be made by substituting an endogenous with a mutated version of the gene, or by mutating an endogenous, e.g., by exposure to carcinogens.
  • heterologous when used with reference to a protein or a nucleic acid indicates that the protein or the nucleic acid comprises two or more sequences or subsequences which are not found in the same relationship to each other in nature.
  • the nucleic acid is typically recombinantly produced, having two or more sequences from unrelated genes arranged to make a new functional nucleic acid.
  • the nucleic acid has a promoter from one gene arranged to direct the expression of a coding sequence from a different gene.
  • the promoter is heterologous.
  • heterologous protein indicates that the protein comprises two or more subsequences that are not found in the same relationship to each other in nature (e.g., a fusion protein).
  • Heterologous accordingly includes those proteins and polynucleotide sequences which are not found in a bacteria in which they are introduced. Such proteins can be of mammalian, primate, human, reptilian, or insect origin.
  • recombinant when used with reference, e.g., to a cell, or nucleic acid, protein, or vector, indicates that the cell, nucleic acid, protein or vector, has been modified by the introduction of a heterologous nucleic acid or protein or the alteration of a native nucleic acid or protein, or that the cell is derived from a cell so modified.
  • recombinant cells express genes that are not found within the native (non-recombinant) form of the cell or express native genes that are otherwise abnormally expressed, under expressed or not expressed at all.
  • isolated refers to a polypeptide or a peptide fragment or polynucleotide which either has no naturally-occurring counterpart or has been separated or purified from components which naturally accompany it, e.g., in normal tissues such as lung, kidney, or placenta, tumor tissue such as colon cancer tissue, or body fluids such as blood, serum, or urine.
  • the polypeptide or peptide fragment or polynucleotide is considered “isolated” when it is at least 70%, by dry weight, free from the proteins and other naturally- occurring organic molecules with which it is naturally associated.
  • a preparation of a polypeptide (or peptide fragment thereof) or polynucleotide of the invention is at least 80%, more preferably at least 90% or 95%, and most preferably at least 99%, by dry weight, the polypeptide (or the peptide fragment thereof), or polynucleotide, respectively, of the invention.
  • a preparation of polypeptide x is at least 80%, more preferably at least 90%, and most preferably at least 99%, by dry weight, polypeptide x. Since a polypeptide or polynucleotide that is chemically synthesized is, by its nature, separated from the components that naturally accompany it, the synthetic polypeptide is "isolated.”
  • An isolated polypeptide (or peptide fragment) or polynucleotide of the invention can be obtained, for example, by extraction from a natural source (e.g., from tissues or bodily fluids); by expression of a recombinant nucleic acid encoding the polypeptide; or by chemical synthesis.
  • a polypeptide or polynucleotide that is produced in a cellular system different from the source from which it naturally originates is "isolated," because it will necessarily be free of components which naturally accompany it.
  • the degree of isolation or purity can be measured by any appropriate method, e.g., column chromatography, polyacrylamide gel electrophoresis, or HPLC analysis.
  • the fusion protein or protein of interest obtained or made according to the invention is isolated or purified into a state comprising at least 90, 95%, 98%, 99%, or 99.9% by weight of the protein as compared to any other proteins.
  • a recombinant chimeric protein Once a recombinant chimeric protein is expressed, it can be identified by assays based on the physical or functional properties of the product, including radioactive labeling of the product followed by analysis by gel electrophoresis, radioimmunoassay, ELISA, bioassays, etc.
  • the encoded protein may be isolated and purified by standard methods including chromatography ⁇ e.g. , high performance liquid chromatography, ion exchange, affinity, and sizing column chromatography), centrifugation, differential solubility, or by any other standard technique for the purification of proteins.
  • chromatography e.g. , high performance liquid chromatography, ion exchange, affinity, and sizing column chromatography
  • centrifugation e.g., centrifugation, differential solubility, or by any other standard technique for the purification of proteins.
  • the actual conditions used will depend, in part, on factors such as net charge, hydrophobicity, hydrophilicity, etc., - and can be apparent to those having skill in the art.
  • the invention also provides methods of making pharmaceutical compositions, wherein a protein or polypeptide made according to the methods of the invention is formulated in a pharmaceutically-acceptable solution for administration to a cell or an animal, either alone or in combination with other components.
  • the protein so obtained can be administered directly to a subject as a pharmaceutical composition.
  • Administration is by any of the routes normally used for introducing such a protein into ultimate contact with the tissue to be treated, preferably the mucosal membrane and epithelial cells.
  • the compositions comprising such proteins are administered in any suitable manner, preferably with pharmaceutically acceptable carriers. Suitable methods of administering such proteins are available and well known to those of skill in the art. Although more than one route can be used to administer a particular composition, a particular route can often provide a more immediate and more effective reaction than another route.
  • compositions comprising the proteins made or obtained according to the invention may be formulated in conventional manner using one or more physiologically acceptable carriers, diluents, excipients or auxiliaries which facilitate processing of the polypeptides into preparations which can be used pharmaceutically. Proper formulation is dependent upon the route of administration chosen.
  • compositions of the present invention are determined in part by the particular composition being administered, as well as by the particular method used to administer the composition. Accordingly, there are a wide variety of suitable formulations of pharmaceutical compositions of the present invention.
  • pharmaceutical compositions can be formulated for topical administration, systemic formulations, injections, transmucosal administration, oral administration, inhalation/nasal administration, rectal or vaginal administrations. Suitable formulations for various administration methods are described in, e.g., Remington 's Pharmaceutical Sciences, 17 th ed. 1985.
  • the proteins made or obtained according to the invention may be formulated as solutions, gels, ointments, creams, suspensions, etc.
  • Systemic formulations include those designed for administration by injection, e.g. subcutaneous, intravenous, intramuscular, intrathecal or intraperitoneal injection, as well as those designed for transdermal, transmucosal, oral or pulmonary administration.
  • the proteins may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hank's solution, Ringer's solution, or physiological saline buffer.
  • penetrants appropriate to the barrier to be permeated are used in the formulation.
  • a composition can be readily formulated by combining the proteins with pharmaceutically acceptable carriers to enable the chimeric proteins to be formulated as tablets, pills, capsules, liquids, gels, syrups, slurries, suspensions and the like.
  • the proteins obtained according to the present invention are conveniently delivered in the form of an aerosol spray from pressurized packs or a nebulizer, with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas.
  • the proteins may also be formulated in rectal or vaginal compositions such as suppositories or retention enemas, e.g., containing conventional suppository bases such as cocoa butter or other glycerides.
  • the heterologous proteins may possess a conformation substantially different than the native conformations of the constituent proteins. In this case, it can be helpful to denature and reduce the chimeric protein and then to cause the protein to re- fold into the preferred confo ⁇ nation.
  • Methods of reducing and denaturing polypeptides and inducing re-folding are well known to those of skill in the art (see Debinski et al, J. Biol. Chem. 268:14065-14070 (1993); Kreitman & Pastan, Bioconjug. Chem. 4:581- 585 (1993); and Buchner et al, Anal. Biochem. 205:263-270 (1992)).
  • Debinski et al. describe the denaturation and reduction of inclusion body polypeptides in guanidine-DTE.
  • the polypeptide is then refolded in a redox buffer containing oxidized glutathione and L-arginine.
  • the SPI-I system can be used to secrete heterologous proteins.
  • An N-terminal secretion tag or signal was fused to the protein, which was placed under the control of a genetic circuit that links its expression to the completion of a functional TTSS.
  • a knockout strain of Salmonella (AinvE), which makes the TTSS leak protein into the media in the absence of host cells (Zierler and Galan, 1995).
  • ADF-3 a well-expressed human protein, we obtained titers in the supernatant of -20-40 mg/L.
  • the gene was codon optimized while minimizing mRNA secondary structure and sequence repetitiveness. The optimized gene was chemically synthesized. This gene is shown to express and secrete at a titer of -10- 100ul/L.
  • chaperones and effectors are expressed from the sicA and sopE promoters. Similar transcriptional ordering has been observed during the assembly of the evolutionarily related flagella basal body in E. coli (Kalir et al., 2001) and Caulobacter crescentus (Laub et al., 2000).
  • the range of on-times is remarkably broad (OD 6 oo 0.1-1.2).
  • Sequences can be optimized for expression in the eubacteria.
  • the amino acid sequences of silks and fibroins contain highly repetitive regions. This often results in a high rate of homologous recombination, protein truncation, and mRNA secondary structure.
  • Computational methods have been designed to overcome these problems. Such tools were applied to the full length ADF-3 dragline silk gene. There is little or no evidence of homologous recombination using this gene. This is evidenced by a single band of protein after even 24 hours of growth ( Figure 9). Multiple bands have been shown to occur when recombination-sensitive proteins are expressed (Arcidiacono et al., 1998).
  • the N-terminal secretion signal is taken from the SptP effector (Lee and Falkow, 2004). This tag interacts with the SicP chaperone, which has the capability of maintaining effectors in a partially unfolded state (Stebbins and Galan, 2001).
  • the secretion signal is 167 amino acids, where residues 15-100 interact with a SicP dimer (Fu and Galan, 1998). It has been shown previously that a small peptide can be inserted into SptP and it will still be delivered through the TTSS to a host cell (Russman et al., 1997).
  • the secretion system was tested with two heterologous proteins.
  • the first is a 24 kD folded human protein (DH domain of intersectin), which was shown previously to express well in bacteria (Rossman et al., 2002).
  • a secretion assay is performed as described previously (Lee and Galan, 2004).
  • Figure 8 shows a time course of DH secretion. Each point represents directly loaded supernatant; additional precipitation was not necessary.
  • protein starts to accumulate 16 hours after inoculation and accumulates over 24 hours.
  • AinvE knockout This has been shown previously to eliminate the need for host cell contact and boost effector expression into the media (Kubori and Galan, 2002). Significantly more protein is obtained in this knockout, especially after 8 hours.
  • Based on a standard curve Sigma Aldridge FLAG-BAP fusion protein P7457
  • we estimate that protein expression is on the order of 20-40 mg/L.
  • the optimized ADF-3 gene also expresses and is secreted (Figure 9), albeit at lower concentrations (10-100 ug/L). It is noteworthy that only a single band occurs at the correct weight, indicating that homologous recombination is not a problem. It is unclear if the lower yield is due to less expression or inefficient secretion. There are no obvious growth defects when ADF-3 is expressed (not shown).
  • the blot is developed by applying 2mL of prepared developer reagent (Pierce Cat# 32209) to the blot on a clean piece of cling wrap for 1 minute. Excess developer is wicked away with Kimwipe and the blot is placed face down on a clean piece of cling film and air bubbles rolled out. The blot is taped into a development cassette and images acquired using chemiluminescent film (Kodak #178-8207). Typical exposure times are 60 - 180 seconds.
  • the bacteria are modified to increase the fraction of bacteria expressing SPI-I as well as the total number of needles using synthetic genetic circuits.
  • SPI-I expression reaches a peak after 16 hours and then decreases in very late stationary phase (not shown). This is due to our experimental design, where the cultures are grown in batch. Bioreactor fermentations will allow us to maintain SPI-I optimal conditions over a longer period of time.
  • the current system utilizes the SptP secretion signal and SicP effector. This is the most studied signal-chaparone pair, but the SptP effector is not highly secreted into the culture media.
  • effector signals are contemplated (e.g., SipA, SopE, and InvJ are secreted to a concentration 100-fold higher (Lee and Galan, 2004).
  • the wild-type sicA promoter and ribosome binding site are used. Higher expression may be achieved by using this promoter to drive T7, which then activates a very strong promoter (Studier et al., 1986). Such methods can be adapted for the TTSS of other bacteria.
  • the number of needles in the bacterium can be increased by expressing the SPI-I activator hilD. For example, by expressing HiID from the arabinose-inducible promoter PBAD (see Figure 17).
  • the secretion system can be based on the 161 amino acid N- terminal secretion signal from SptP, which interacts with the SicP chaperone (Fu and Galan, 1998). This pair was chosen because it has been extensively studied and demonstrated to provide specificity towards the SPI-I TTSS (Lee and Galan, 2004). However, it is somewhat disadvantageous as it is large and full-length SptP is only moderately secreted into cultures (Lee and Falkow, 2004). Thus additional secretion signals are contemplated.
  • two additional secretion signals can be cloned at the N-terminal end of ADF-3 and DH.
  • a second secretion signal can be taken from the SopE effector, which interacts with the chaperone InvB (Lee and Galan, 2003). This effector is secreted in large amounts into the media.
  • the first 100 amino acids can be used as the signal because it has been shown to include the chaperone binding domain (Lee and Galan, 2003).
  • the SipA effector is secreted into the media at high titer, but its chaperone is SicA and, in some embodiments, might interfere with the SicA/InvF genetic circuit that we are using to induce.
  • different signal-chaparone pairs may be optimal for secreting different types of proteins.
  • the SicP chaperone maintains proteins in a partially unfolded state, which may be important for the secretion of folded proteins (Stebbins and Galan, 2001).
  • biopolymers do not have significant internal structure and may not require active maintenance in an unfolded state. In this case, a shorter signal, such as InvJ, may be adequate.
  • the DH domain which is a stable and folded protein, helps assess whether a secretion signal requires that a protein be unfolded.
  • the AinvE strain is used. This strain significantly increases the titer of protein in the culture media.
  • additional directed knockouts are contemplatedto increase the titer of expressed protein.
  • genes can be knocked out to remove competitive secretion systems, effectors, and proteases.
  • the SPI-I TTSS is co-regulated with the SPI-2 system and flagella (Deiwick et al., 1998; Eichelberg and Galan, 2000).
  • flagella There are regulatory interactions that ensure mutually exclusive interactions between systems. For example, when flagella are expressed, SPI-I is repressed. All three of these systems are expressed at different stages of growth in LB media. Cells that express one system do not express the other, which leads to a smaller fraction expressing SPI-I. To increase this fraction, the flhDIC master regulators of flagella assembly (Liu and Matsumura, 1994) and the ssrAB two-component system that controls SPI-2 (Feng et al., 2003) can be knocked out.
  • Embodiments with these knockouts have the added benefit of reducing the amount of proteins in the supernatant.
  • SPI-I effectors remain encoded in the genome.
  • these proteins will not compete for secretion.
  • the invJ and sipB/C effectors are preferably left intact because of their involvement in the construction and function of the needle (Collazo and Galan, 1996; Kubori et al., 2000).
  • Embodiments employing the sicA promoter are contemplated as it is a relatively strong promoter that is turned on late in the growth stage.
  • other strong promoters can be integrated into the pertinent control circuits.
  • synthetic genetic circuits can be constructed to increase expression from the Sic/4 promoter.
  • the sic A promoter can be set to drive the expression of the T7 transcriptional activator.
  • the heterologous protein then can be expressed from a very strong T7 promoter (Studier et al., 1986). This circuit functions like an 'amplifier' to increase expression. Expression would still be linked to the completion of the TTSS structure and no chemical inducer would be required.
  • T7 Another advantage of using T7 is that it is not subject to rho-termination, making it less prone to producing protein truncation products (Fahnstock et al., 2000).
  • Overexpression can be balanced against other variables for further improvements. If the protein is particularly toxic or tends to particularly forms inclusion bodies, then higher levels of over expression could slow growth. In addition, with too high an overexpression, the secretion systems could be 'maxed out,' in which case the number of needles and secretion speed would be the rate determining step. Or, for instance, the chaperone sicP could be saturated and unable to deliver a higher concentration of effector to the needle. Maximizing yield may therefore require additional genetic manipulations to bolster the limiting factors.
  • DNA optimization and expression of natural biopolymers is generally contemplated as an important subgroup of proteins of interest. These proteins include the natural protein- based biopolymer genes of Table 1.
  • NDF-4 627 fibroin 1 Euagrus chisoseus 734 fibroin 2
  • Nephila clavipes 387 minor ampullate silk Nephila clavipes 251 spidroin 1 Kukulcania hibernalis 760 spidroin 2-1 Kukulcania hibernalis 185
  • Non-spider Silks light chain Bombyx mori 262 heavy chain Bombyx mori 633 sericin IA Bombyx mori 779 heavy chain Galleria mellonella 443 silk gum protein 1 Galleria mellonella 1 15 silk gum protein 2 Galleria mellonella 220 light chain Galleria mellonella 267
  • These polymers include dragline proteins from different spiders. Additional fibroins are included that represent threads with different material properties. For example, the web radial threads and safety line (ampullate), sticky spiral threads (flagelliform), and egg sack (cylindrical) silks all have different physical properties (Dicko et al., 2004).
  • the genes from other species, such as moths and silk worms can be included. In particular, the extreme repetitive nature of silk worm silk has made it a hard target for recombinant technologies. The rubber-like resilin from Drosphila can also be expressed (Elvin et al., 2005).
  • Other interesting biopolymers can be included from non-insect species.
  • Mollusk abductin which is an extremely strong glue-like protein with be synthesized (Bochicchio et al., 2005).
  • interesting human biopolymers that make up the extracellular matrix - elastin, collagen, and elastin microfibril proteins - have applications in the coating of medical devices (Mongiat et al., 2000). Such proteins may be used as a fusion protein having the short secretion tag still attached or as a protein in which the tag has been removed.
  • the biopolymer genes can be codon optimized for eubacterial expression, while minimizing the DNA repetitiveness and mRNA secondary structures. Gene optimization and chemical synthesis are commercially available (e.g., GeneDesigner by DNA 2.0) to optimize sequences for translation. The sequence is then broken into oligonucleotides which are assembled either by annealing and ligation or annealing and extension (Prodromou and Pearl 1992; Yo et al. 2003). [0166] The simplest way to design a DNA sequence from an amino acid sequence is to assign the most abundant codon to all instances of that amino acid in the sequence. Codon usage preference in a gene is often measured by Codon Adaptation Index (CAI score).
  • CAI score Codon Adaptation Index
  • the CAI score for such a construct is 1.0, i.e. in each case only the most abundant codon is used.
  • a strongly transcribed mRNA from such a gene can generate high codon concentrations for a subset of the tRNA populations, resulting in imbalanced tRNA pool, skewed codon usage pattern and increased translational error (Kurland and Gallant 1996).
  • Heterologously expressed proteins may be produced at levels as high as 60% of total cell mass, making an imbalance tRNA pool a significant problem resulting in reduced growth due to tRNA depletion (Gong M, Gong F et al.
  • Gene Designer optimizes genes for expression by using a codon usage table in which each codon is given a probability score based on the frequency distribution of the codons in the genome normalized for every amino acid.
  • Candidate sequences are generated in silico using a Monte Carlo algorithm by selecting codons based on the probabilities obtained from the codon usage table, with codons below the threshold value (default is 10%) excluded from consideration.
  • Each designed sequence is then passed through subsequent iterations to ensure a match with additional design criteria such as filtering out mRNA secondary structures and DNA repeats, eliminating or incorporating restriction sites and avoiding methylation sites that overlap methylation sensitive restriction sites (Gustafsson, Govindarajan et al. 2004).
  • the local context of a codon can influence the protein expression levels.
  • the efficiency of the UAG stop codon in E. coli is typically decreased in the presence of a 3' adenine and increased in the presence of a 3' cytidine (Bossi and Roth 1980; Miller and Albertini 1983).
  • Gene Designer avoids known codon context issues by omitting the use of rare codons and filtering out runs of Cs and G's. [0168] Gene Designer does not utilize advanced RNA folding calculation software such as the popular mFold (Zuker 2003) as these types of software are designed to calculate RNA secondary structures for naked RNA. The translated mRNA within an ORF is in fact densely covered by ribosomes.
  • Backtranslation with Gene Designer is performed in 2 stages.
  • First a sequence encoding the desired amino acid sequence is selected by choosing each codon probabilistically using a codon bias table appropriate for the expression organism.
  • Second an evolutionary algorithm is employed to remove excluded restriction sites, RNA secondary structure and repeated sequence elements. This algorithm compares the designed sequence with the additional constraints (such as the longest permitted repeat, the restriction enzyme recognition sequences that should not occur) and identifies codons that are part of regions that do not conform to the required specifications. These codons are then independently replaced by synonymous codons, again selected probabilistically from the codon bias table. A replacement that brings the sequence design closer to conforming to the additional constraints is accepted, otherwise it is rejected. This process is iterated hundreds or thousands of times until the constraints are met.
  • each gene After each gene is synthesized, it can be placed in the Salmonella secretion strain.
  • a FLAG-tag can be synthesized at the end of each fibroin, such that the concentration can be determined using a Western analysis.
  • the secretion assays can be performed and the total protein can be quantified in the pellet lysate and supernatant. This can provide the total amount of protein produced and secreted, which can be used to determine if low yields are an expression or secretion problem. Assaying for expression and secretion of each biopolymer or protein in Salmonella expression system or other expression systems.
  • proteins in fluid medium are well known to one of ordinary in the art. They can be based upon antibody binding assays, competitive displace assays, gel electrophoresis and staining assays, column chromatography, and the like.
  • the proteins can be tagged with a fluorescent protein label such as GFP to facilitate their detection.
  • the label can be joined to the protein by an amino acid sequence specifically subject to hydrolysis by chemical means or by contact with a predetermined protease to release the unlabeled protein.
  • the SPI-I initiation regulator hilD can be knocked out and placed under inducible control by use of constructed hybrid SPI-I promoters that are IPTG- inducible.
  • a protease site e.g., a TEV protease site
  • a late stage TTSS promoter can be used to control TEV expression.
  • the SPI-I regulation can be used to program a series of events into the bacterium, where a protein is first secreted and then modified. Both of these events may occur in the supernatant or growth medium.
  • a system can express a heterologous protein, and then automatically cleave the secretion signal. This can be done by placing the protein under the control of the sicA promoter, and then the protease under the control of a promoter that turns on at a higher cell density. The protease can be exposed to the extracellular environment and cleave the N-terminal signal from the secreted protein.
  • This system can provide a microbial biopolymer factory where each component is expressed in a precise, temporally regulated order.
  • IPTG-inducible SPI-I promoters are used.
  • the SPI-I regulatory cascade can be exploited to control the expression of different genes at different stages of growth.
  • IPTG-dependent SPI-I promoters one can construct a set of IPTG-dependent SPI-I promoters.
  • the addition of IPTG to the media can unlock all of the promoters, but they retain their timing. In this way, the entire 'assembly line' can be activated at once and expression can be avoided during the growth and maintenance of the strain.
  • inclusion of lacO binding sites up and downstream of an arbitrary promoter to repress its activity is contemplated(Law et al., 1993; Muller et al., 1996).
  • a component of this repression is DNA looping.
  • this repression is optimal (Muller et al., 1996).
  • Synthetic promoters can be constructed by flanking SPI-I and other Salmonella promoters by lacO binding sites and testing to determine if the promoter can be induced by IPTG. To obtain a range of on-times, IPTG-inducible sicA, ssaG, and spvA promoters can be constructed (Grob et al., 1997; McKelvie et al., 2004).
  • a TEV protease cleavage site can be placed between the N-terminal secretion signal and the heterologous protein.
  • the TEV protease is small, well-characterized, and only leaves a single alanine attached to the protein.
  • the protease may be fused into the AIDA presentation system (Maurer et al., 1997), such that it remains tethered to the outer membrane of the bacterium.
  • the TEV-AIDA construct can be placed under the control of the ssaG promoter, which turns on in a subtraction of the cell population at a late stage of growth.
  • the assay to monitor this system can be run a time course of secreted protein and track the products by western blot.
  • a SptP-DH protein for instance, may be expressed and secreted and then the TEV protease automatically cleaves the 167 amino acid N-terminal signal.
  • the IPTG-inducible promoters allow the entire system to be induced during growth such that the protease and heterologous protein do not accumulate during the growth and maintenance of the strain.
  • cellulases or other enzymes are the heterologous protease to be secreted.
  • the bacteria can be engineered and the heterologous enzymes to be secreted selected according to a predetermined nutrient supply.
  • the biomass converting cellulases, hemicellulases, and glycosyl hyrdrolases represent a naturally-secreted enzyme mixture that is of significant industrial interest.
  • These enzymes are secreted by fungi and bacteria in the course of breaking down plant biomass as a carbon source. These enzymes have been produced industrially to convert biomass to fermentable sugars to produce ethanol as an inexpensive biofuel.
  • Cellulase production may be the most expensive step during ethanol production from cellulosic biomass, in that it can account for approximately 40% of the total cost (Spano et al., 1975). Significant cost reduction is required in order to enhance the commercial viability of cellulase production technology.
  • a cellulosic enzyme system consists of three major components: endo- ⁇ -glucanase (EC 3.2.1.4), exo- ⁇ -glucanase (EC 3.2.1.91) and ⁇ -glucosidase (EC 3.2.1.21). The mode of action of each of these being:
  • Exo-P-glucanase, 1,4- ⁇ - D-glucan cellobiohydrolase, Avicelase, Cl exo-attack on the non-reducing end of cellulase with cellobiose as the primary structure.
  • Amyris Biotechnologies Inc. has engineered an E. coli strain that contains a nine-enzyme pathway much like the biosynthetic pathway in the plant Artemisia annua, responsible for the production of the anti-malarial drug, artemisinin (Martin et al., 2003).
  • This engineered cell is capable of producing up to 20 g/L of the anti-malarial drug precursor in high-density fermentations.
  • Shake flask experiments using the same system is Salmonella enterica have yielded similar results.
  • ADF-I is expressed in the minor ampullate gland and forms the radial spokes of a thread, which have high tensile strength, but are inelastic (Gosline et al., 1999; Guerette et al., 1996).
  • ADF-2 is expressed in the cylindrical gland (egg sacks) and has a sequence that is similar to human elastins.
  • ADF-3 and ADF-4 are expressed in the major ampullate gland and form the extremely tough and elastic dragline, which forms the frame of the web.
  • the wild-type DNA sequences of these genes contain rare codons as well as large repetitive regions ( Figure 14).
  • Figure 14 In the case of ADF-4, there are two sets of DNA repeat units >100 bp with exact identity.
  • Each gene was computationally optimized to eliminate rare codons, repetitive units, and reduce mRNA secondary structure.
  • the optimized genes shared only 24-29% of the wild type codons. The optimizations were performed on the full available amino acid sequence, including non-repetitive N- and C-terminal domains, which have a role in solubility and the self-assembly of fibrils (Jin et al., 2003).
  • TTSS bacterial type III secretion system
  • SPI-I Salmonella Pathogeneity Island 1
  • the SPI-I TTSS is advantageous because it has been well-characterized and the needles are highly expressed under standard laboratory conditions (Lundberg et al., 1999).
  • the TTSS is unique because it translocates polypeptides through both the inner and outer membranes. This is in contrast to the sec and TaT pathways, which deliver proteins to the periplasm (Wickner et al., 2005; Georgiou et al., 2005).
  • Type II secretion can export proteins from the periplasm through the outer membrane; however, the secretion signal is difficult to identify and appears to be distributed throughout the protein, making heterologous secretion difficult (Polschroder et al., 2005; Francetic et al., 2005).
  • Salmonella uses a genetic circuit to avoid the expression of effector proteins until secretion needles have been constructed and are functional ( Figure 12a) (Kalir et al., 2001). This circuit governs the activation of the sicA promoter, which controls the transcription of effector and chaperone genes. This promoter is turned on by the InvF transcription factor, which is only active when bound to the SicA chaperone. Prior to the completion of the TTSS, the SicA chaperone is sequestered by the SipB/C effectors(Tucker et al., 2000). Once the TTSS is functional, SipB/C secrete, thus freeing the chaperone to activate the transcription factor. This positive feedback loop amplifies the expression of effectors to match the capability of the cell to export protein.
  • the SicA gene circuit forms the core of our synthetic genetic system (pCASP) to secrete heterologous proteins.
  • the sicA promoter has a low basal transcription rate and increases 200-fold in activity once the TTSS is functional ( Figure 12c).
  • the sicA promoter drives the expression of the heterologous protein, which is fused to an N-terminal secretion signal from the SptP effector protein (Lee et al., 2004).
  • a tobacco etch virus (TEV) protease site is added after the signal sequence, such that the secretion signal can be cleaved after export.
  • the SptP signal sequence interacts with the SicP chaperone, which directs the SptP tagged protein to the SPI-I needle ((Akeda et al., 2005; Stebbins et al., 2001).
  • the SicP chaperone is overexpressed with the secretion-tagged heterologous protein.
  • the wild-type ribosome binding sites are preserved for both SicP and SptP to ensure that the native ratio of chaperone: effector is maintained.
  • heterologous protein secretion was tested using a 24kD human protein (DH domain), which expresses well in Salmonella (Figure 13).
  • a secretion assay was performed to determine the amount of exported protein (Supplementary Information) (Collazo et al., 1996). After the SPI-I secretion apparatus is assembled, there is a steady increase in the amount of DH protein secreted ( Figure 13b). After 8 hours of growth in SPI-I media, 60 mg/L of protein was detected. When DH lacking the secretion tag was expressed using an inducible system, the protein was detected in the cell lysate, but not after a secretion assay.
  • the secretion efficiency was calculated by determining the amount expressed inside the bacteria to the amount that is secreted. In the case of ADF-3, 5.2 mg/L is detected in the lysate, yielding a secretion efficiency of 50% in eight hours (supplementary information). When the N-terminal tag is removed, slightly more is detected in the lysate (5.9 mg/L), but much less is present in the supernatent (200 ⁇ g/L) and can only be detected after concentration.
  • Salmonella typhimurium SLl 344 was used for all secretion experiments (gift of Stanley Falkow, Stanford).
  • a flagella knockout was created by deleting the FIhCD transcriptional activators [Genbank ID: 1253445 and 1253446] ( ⁇ FlhCD::KanR) using the method of Datsenko and Wanner in the Salmonella genome.
  • the pCASP plasmid [Genbank ID: bankit870464] was constructed based on pPROTet.133 backbone (Cm R , CoIEl) (BD Clonetech).
  • sicA promoter 165 bases upstream of the sicA start codon
  • sicP gene and first 160 amino acids of sptP, including the start codon [Genbank ID: 1254401, (3030898 - 3022551)] were obtained by PCR of Salmonella typimuirum SL1344 genomic DNA.
  • a TEV protease cleavage sequence (GENLYFQSG), flanked by glycines for flexibility, was inserted by PCR primer between the SptP tag and the HindIII site. Open reading frames for DNA were inserted between the HindIII and Xbal restriction sites.
  • a FLAG epitope tag (DYKDDDDK) was introduced non-directionally at the Xbal site for detection by western blot.
  • the DH plasmid lacking the N-terminal secretion signal and SicP was constructed using the pBAD30 backbone with the DH ORF inserted between the Kpnl and Xbal sites.
  • Manipulation of plasmids was done in E. coli strains XLl, MC1061, and OmniMAX (DNA 2.0). Media was supplemented with 25 ug/mL Kanamycin, 30 ug/mL Choloramphenicol or 100 ug/mL Ampicillin as needed.
  • the reporter plasmids are constructed based on the pPROTet Cm' system (CoIEl ori) available from Clontech/BD (Cat# 631203).
  • the SPI-I promoters were cloned from Salmonella enterica Typhimurium SLl 344 genomic DNA, transcriptionally fused with green fluorescent protein (gfpmut3) using SOEing PCR, and ligated into pPRO using the Xhol/Xbal restriction sites.
  • a large upstream region associated with each promoter was cloned: hilD (- 312), hilC (-432), prgH (-317), sicA (- 166).
  • the secretion assay was performed as described previously (Collazo et al., Infect Immune, 1996).
  • the TTSS was induced in high-salt LB (LB Miller + 7g NaCl achieving a total NaCl concentration of 0.3M) and uninduced in LB-Lennox (L).
  • Cells were plated on L- broth agar plates from frozen stock and grown overnight on L-broth agar. Single colonies were picked and grown 10 hours overnight in 5 ml liquid L broth. The overnights were diluted 1 :100 into 5mL fresh L-broth cultures and grown for 2 hours at 250 rpm.
  • the cultures were then diluted 1 : 10 into 5OmL of inducing media in a non-baffled 25OmL glass flask.
  • the cultures were grown at 37°C for 8 hours at 160 rpm.
  • Supernatants were harvested by spinning cultures at 350Og for 30 minutes followed by vacuum filtration through 0.45um cellulose acetate filter unit (Corning Cat# 430314).
  • sample proteins were either precipitated in 10% trichloroacetic acid (TCA) for 1 hour and recovered or unconcentrated supernatant samples were collected.
  • Samples were prepared in SDS sample buffer under reducing conditions and boiled for 3-5 minutes before PAGE analysis. Precipitated protein preparations were used only in the Coomassie gel and MaIE western blot.
  • Samples for TEV proteolysis were prepared by collecting supernatants and combining undiluted sample with concentrated TEV sample buffer and recombinant TEV protease (Invitrogen Cat# 12575-015). TEV digests were run for 1 hour at room temperature before addition of SDS sample buffer under reducing conditions and analyzed by PAGE.
  • DNA 2.0 used in-house developed software (GeneDesigner) to optimize sequences for expression and translation.
  • GeneDesigner used in-house developed software (GeneDesigner) to optimize sequences for expression and translation.
  • the degeneracy of the genetic code enables many alternative nucleotide sequences to encode the same protein.
  • the frequencies with which different codons are used by different organisms and different types of genes vary significantly and are correlated to the concentration of the corresponding tRNA population in the cell.
  • Each codon is given a probability score based on the frequency distribution of the codons in the genome normalized for every amino acid. Codons in the synthetic gene are then assigned from this table to create a new gene sequence.
  • Gene Designer filters out (or flags, if it can not be avoided) any mRNA structure with double-stranded RNA stem of 12 bp or more.
  • oligonucleotides used in the gene synthesis process do not predominantly self-anneal during gene assembly.
  • sequence is broken into oligonucleotides, which are assembled either by annealing and ligation or annealing and extension.
  • the cultures are grown in a shaker at 37 0 C at 160 rpm. During growth, 1 ml aliquots are taken every 20 min and the OD 6 oo is measured, the cells are spun down, resuspended in 200 ⁇ l PBS with 2 mg/ml Kanamycin and put on ice to stop gfp expression.
  • the data shown in Figure 23 includes data from four growth experiments performed on different days.
  • Flow Cytometry data was obtained on a BD FACSCalibur system as part of the UCSF core facility. Each bacterial dataset consists of at least 30,000 cells. The data is gated by forward and side scatter to observe bacteria-sized particles. Data analysis is performed using the WINMIDI program.
  • the expression plasmid for heterologous secretion is shown Figure 15.
  • A (Genbank: ).
  • the plasmid is based on the pPRO backbone with a CoIE 1 ori and Cm R .
  • the sicA promoter drives the expression of the chaperone SicP as well as the protein to be secreted.
  • the secreted protein is fused to the N-terminal 160 amino acids of SptP.
  • a TEV protease site is included so that the tag can be cleaved post-secretion.
  • the plasmid is designed such that the Hindlll/Xbal sites can be used to insert different genes to be secreted.
  • FLAG tag was synthesized as part of the ORF in the case of ADF-I, 2, 4. For ADF-3, it was added synthetically to the pCASP plasmid at the Xbal site.
  • Bini, E, Knight, DP, and Kaplan, DL (2004) Mapping domain structures in silks from insects and spiders related to protein assembly, J. MoI. Biol., 335: 27-40.
  • Fahnestock SR, Yao, Z, and Bedzyk, LA (2000) Microbial production of spider silk proteins, Rev. MoI. Biotechnology, 74: 105-119. Farabaugh, P. J. and G. R. Bj ⁇ rk (1999). "How translational accuracy influences reading frame maintenance.” Embo J 18(6): 1427-34.
  • InvB is a type III secretion-associated chaperone of the Salmonella enterica effector protein SopE, J. Bacterid., 185: 7279-7284.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Microbiology (AREA)
  • Insects & Arthropods (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention concerne des protéines, un polynucléotide, une cassette d'expression, un vecteur et des compositions bactériennes permettant d'obtenir des protéines d'intérêt par l'expression des éléments susdits dans des bactéries à Gram négatif qui présentent un système de sécrétion de type III. L'invention concerne également les utilisations des protéines ainsi obtenues pour la fabrication de protéines isolées, de soies, de fibres, de fils ainsi que des compositions pharmaceutiques.
PCT/US2007/069300 2006-05-18 2007-05-18 Production de biopolymères et de protéines au moyen de systèmes de sécrétion de type iii de bactéries à gram négatif Ceased WO2008019183A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80175806P 2006-05-18 2006-05-18
US60/801,758 2006-05-18

Publications (2)

Publication Number Publication Date
WO2008019183A2 true WO2008019183A2 (fr) 2008-02-14
WO2008019183A3 WO2008019183A3 (fr) 2008-12-04

Family

ID=39033539

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/069300 Ceased WO2008019183A2 (fr) 2006-05-18 2007-05-18 Production de biopolymères et de protéines au moyen de systèmes de sécrétion de type iii de bactéries à gram négatif

Country Status (1)

Country Link
WO (1) WO2008019183A2 (fr)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015078840A1 (fr) * 2013-11-26 2015-06-04 Boehringer Ingelheim International Gmbh Sécrétion totale ou partielle d'une protéine et présentation à la surface d'une cellule au moyen d'un système de sécrétion de type iii
WO2015177197A1 (fr) * 2014-05-21 2015-11-26 Universitaet Basel Largage de protéines à base de bactéries
WO2017085235A1 (fr) * 2015-11-19 2017-05-26 Universität Basel Administration de protéines basée sur des bactéries
WO2017087827A1 (fr) * 2015-11-19 2017-05-26 President And Fellows Of Harvard College Fabrication de soie recombinante et de protéines hybrides amyloïdes et de soie au moyen de bactéries
WO2018132821A3 (fr) * 2017-01-13 2018-08-23 Bolt Threads, Inc. Protéines élastomères
WO2019090267A1 (fr) * 2017-11-03 2019-05-09 The Regents Of The University Of California Procédés et compositions utiles pour inhiber la croissance de certaines bactéries
US11166987B2 (en) 2015-11-19 2021-11-09 Universitaet Basel Virulence attenuated bacteria for treatment of malignant solid tumors
EP3932937A1 (fr) * 2020-07-03 2022-01-05 Universitätsklinikum Hamburg-Eppendorf Nouveau domaine de translocation de protéines
US11518789B2 (en) 2016-12-20 2022-12-06 Universitaet Basel Virulence attenuated bacteria based protein delivery
US12268275B2 (en) 2018-07-18 2025-04-08 Bolt Threads, Inc. Cross-linked elastomeric proteins in polar nonaqueous solvents and uses thereof
US12351805B2 (en) 2015-11-19 2025-07-08 Northeastern University Method of making recombinant silk and silk-amyloid hybrid proteins using bacteria
US12391912B2 (en) 2021-10-26 2025-08-19 Rensselaer Polytechnic Institute Systems and methods for increased production of recombinant biopolymers via genome engineering and downregulation of basal expression

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DARWIN ET AL.: 'The putative invasion proteiin chaperone SicA acts together with InvF to activate the expression of Salmonella typhimurium virulence genes' MOL. MICROBIOL. vol. 35, no. 4, February 2000, pages 949 - 960 *
GUZMAN ET AL.: 'Direct expression of Bordetella pertussis filamentous hemagglutinin in Escherichia coli and Salmonella typhimurium aroA' INFECT. IMMUN. vol. 59, no. 10, October 1991, pages 3787 - 3795 *
WINSTANLEY ET AL.: 'Type III secretion systems and pathogenicity islands' J. MED. MICROBIOL. vol. 50, no. 2, February 2001, pages 116 - 126 *

Cited By (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015078840A1 (fr) * 2013-11-26 2015-06-04 Boehringer Ingelheim International Gmbh Sécrétion totale ou partielle d'une protéine et présentation à la surface d'une cellule au moyen d'un système de sécrétion de type iii
WO2015177197A1 (fr) * 2014-05-21 2015-11-26 Universitaet Basel Largage de protéines à base de bactéries
KR20170010803A (ko) * 2014-05-21 2017-02-01 우니페르시테트 바젤 세균 기반 단백질 전달
US12091670B2 (en) 2014-05-21 2024-09-17 Universitaet Basel Bacteria-based protein delivery
JP7509821B2 (ja) 2014-05-21 2024-07-02 ウニヴェルズィテート バーゼル 細菌に基づくタンパク質送達
JP2017517257A (ja) * 2014-05-21 2017-06-29 ウニヴェルズィテート バーゼル 細菌に基づくタンパク質送達
CN107001431A (zh) * 2014-05-21 2017-08-01 巴塞尔大学 基于细菌的蛋白质递送
IL283280B2 (en) * 2014-05-21 2023-08-01 Univ Basel Providing bacteria-based proteins
CN115960919A (zh) * 2014-05-21 2023-04-14 巴塞尔大学 基于细菌的蛋白质递送
IL283280B1 (en) * 2014-05-21 2023-04-01 Univ Basel Providing bacteria-based proteins
EP3660034A1 (fr) * 2014-05-21 2020-06-03 Universität Basel Administration de protéines à base de bactéries
AU2015261905B2 (en) * 2014-05-21 2020-07-09 Universitaet Basel Bacteria-based protein delivery
CN107001431B (zh) * 2014-05-21 2022-11-01 巴塞尔大学 基于细菌的蛋白质递送
US10889823B2 (en) 2014-05-21 2021-01-12 Universitaet Basel Bacteria-based protein delivery
KR102440293B1 (ko) * 2014-05-21 2022-09-05 우니페르시테트 바젤 세균 기반 단백질 전달
JP2022109967A (ja) * 2014-05-21 2022-07-28 ウニヴェルズィテート バーゼル 細菌に基づくタンパク質送達
US11365225B2 (en) 2015-11-19 2022-06-21 President And Fellows Of Harvard College Method of making recombinant silk and silk-amyloid hybrid proteins using bacteria
IL259050B1 (en) * 2015-11-19 2023-11-01 Univ Basel Bacteria-based protein delivery
US12351805B2 (en) 2015-11-19 2025-07-08 Northeastern University Method of making recombinant silk and silk-amyloid hybrid proteins using bacteria
US11166987B2 (en) 2015-11-19 2021-11-09 Universitaet Basel Virulence attenuated bacteria for treatment of malignant solid tumors
WO2017085235A1 (fr) * 2015-11-19 2017-05-26 Universität Basel Administration de protéines basée sur des bactéries
WO2017087827A1 (fr) * 2015-11-19 2017-05-26 President And Fellows Of Harvard College Fabrication de soie recombinante et de protéines hybrides amyloïdes et de soie au moyen de bactéries
EA039922B1 (ru) * 2015-11-19 2022-03-28 Университет Базель Доставка белка бактериями
AU2016355975B2 (en) * 2015-11-19 2022-12-08 Universität Basel Bacteria-based protein delivery
IL259050B2 (en) * 2015-11-19 2024-03-01 Univ Basel Bacteria-based protein delivery
JP2019500027A (ja) * 2015-11-19 2019-01-10 ウニヴェルズィテート バーゼル 細菌に基づくタンパク質送達
US11702663B2 (en) 2015-11-19 2023-07-18 Universität Basel Bacteria-based protein delivery
US11518789B2 (en) 2016-12-20 2022-12-06 Universitaet Basel Virulence attenuated bacteria based protein delivery
US12358955B2 (en) 2016-12-20 2025-07-15 Universitaet Basel Virulence attenuated bacteria based protein delivery
WO2018132821A3 (fr) * 2017-01-13 2018-08-23 Bolt Threads, Inc. Protéines élastomères
US11858971B2 (en) 2017-01-13 2024-01-02 Bolt Threads, Inc. Elastomeric proteins
EP3568408A4 (fr) * 2017-01-13 2020-12-16 Bolt Threads, Inc. Protéines élastomères
US10988515B2 (en) 2017-01-13 2021-04-27 Bolt Threads, Inc. Elastomeric proteins
WO2019090267A1 (fr) * 2017-11-03 2019-05-09 The Regents Of The University Of California Procédés et compositions utiles pour inhiber la croissance de certaines bactéries
US12268275B2 (en) 2018-07-18 2025-04-08 Bolt Threads, Inc. Cross-linked elastomeric proteins in polar nonaqueous solvents and uses thereof
EP3932937A1 (fr) * 2020-07-03 2022-01-05 Universitätsklinikum Hamburg-Eppendorf Nouveau domaine de translocation de protéines
US12391912B2 (en) 2021-10-26 2025-08-19 Rensselaer Polytechnic Institute Systems and methods for increased production of recombinant biopolymers via genome engineering and downregulation of basal expression

Also Published As

Publication number Publication date
WO2008019183A3 (fr) 2008-12-04

Similar Documents

Publication Publication Date Title
WO2008019183A2 (fr) Production de biopolymères et de protéines au moyen de systèmes de sécrétion de type iii de bactéries à gram négatif
Zoued et al. Architecture and assembly of the Type VI secretion system
Chow et al. Ultra‐high expression of a thermally responsive recombinant fusion protein in E. coli
Zhao et al. Comparative genomics reveal pathogenicity‐related loci in Pseudomonas syringae pv. actinidiae biovar 3
KR20180029953A (ko) 세포 또는 유기체의 게놈으로의 ＤＮＡ 서열의 표적화 혼입을 위한 Ｃａｓ 9 레트로바이러스 인테그라제 시스템 및 Ｃａｓ 9 재조합효소 시스템
EP1791961B1 (fr) Procede de production d'une proteine utilisant la proteine yebf
CN112063648A (zh) 一种草莓果实蔗糖积累相关重要转录调控因子的基因、编码蛋白及其应用
CN107955067A (zh) 参与桃黄酮醇生物合成调控的两个myb转录因子及其应用
CN114761044A (zh) 编码嵌合视紫红质的核酸构建体
CN103797122A (zh) 用于大肠杆菌中异源蛋白质生产的新的表达和分泌载体系统
JP5771833B2 (ja) 核酸、核酸によりコードされるタンパク質、核酸が導入された組換え生物、及び組換え生物により作られるタンパク質
Widmaier et al. Quantification of the physiochemical constraints on the export of spider silk proteins by Salmonella type III secretion
CN112391396B (zh) 构建于大肠杆菌中的粪肠球菌群体感应基因开关系统及其表达载体、工程菌和应用
CN120441673A (zh) 麦红吸浆虫抗禾谷镰刀菌多肽SmAFP及其应用
DK2451954T3 (en) Modified promoter
CN104531712B (zh) 具有杀菌活性的烟粉虱肽聚糖识别蛋白的制备及应用
KR102488022B1 (ko) 재조합 실크 단백질 생산능이 향상된 재조합 미생물 및 이를 이용한 고분자량 재조합 실크 단백질의 생산 방법
KR102809778B1 (ko) 조절가능한 리보솜 번역 속도를 위한 조성물 및 사용 방법
CN111019948A (zh) 一种丰原素合成代谢调控基因FenSr3及其应用
US10023619B1 (en) Production of spider silk protein in corn
CN102094026B (zh) 激发植物产生过敏反应的蛋白质HlpB基因
CN105218633B (zh) 甲酸切割位点肽及其相关生物材料与它们在生产降钙素中的应用
CN105367631B (zh) 一种转录激活子样效应因子核酸酶及其编码基因和应用
CN113214409B (zh) 一种蜂毒素-死亡素杂合肽突变体mtm及其应用
Widmaier Engineering the Salmonella Type III Secretion System

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07840188

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07840188

Country of ref document: EP

Kind code of ref document: A2